Clinical Study

Ef-32: Pivotal, Randomized, Open-Label Study Of Optune® (Tumor Treating Fields, 200Khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma

Posted Date: May 20, 2021

  • Investigator: Kyle Wang
  • Specialties: Cancer, Oncology
  • Type of Study: Device & Drug

The purpose of this study is to test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy. Effectiveness will be determined by measuring Overall Survival Rate.


Must Have Confirmed Diagnosis Of Gbm, Planned Treatment With Rt/Tmz Followed By Ttfields And Maintenance Tmz, Karnofsky Performance Status = 70, Life Expectancy = Least 3 Months, No Progressive Disease, No Significant Co-Morbidities At Baseline Which Would Preclude Maintenance Rt Or Tmz Treatment, As Determined By The Investigator, No Implanted Pacemaker, Defibrillator, Deep Brain Stimulator, Other Implanted Electronic Devices In The Brain, Or Documented Clinically Significant Arrhythmias, No Evidence Of Increased Intracranial Pressure, No Skull Defects


Glioblastoma, Gbm, Radiation

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.